The histone modifier KMT2A was recently nominated to be a regulator of aberrant WNT/β-catenin signaling by a genome-scale CRISPR screen in DLD1 CRC cells engineered to express fluorescence-based reporter at the endogenous locus of either AXIN2 or cMYC, direct targets of β-catenin19. This evidence concerns the gene KMT2A and colorectal carcinoma.